[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fIdi9TuJu2I6iHG4STJ526oJQfGBU3JVN4M-5UD49A4s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Alnylam Pharmaceuticals",[4],82,false,24,15,24825,16,10,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"TTR-mediated Amyloidosis",8,{"name":18,"count":19},"Hypertension",6,{"name":21,"count":22},"Acute Hepatic Porphyria",5,{"name":24,"count":25},"Primary Hyperoxaluria",4,{"name":27,"count":25},"Amyloidosis, Hereditary",{"name":29,"count":30},"Healthy Volunteers",3,{"name":32,"count":30},"Primary Hyperoxaluria Type 1 (PH1)",{"name":34,"count":30},"Respiratory Syncytial Virus Infections",[36,41,46,51,56,61,66,71,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04153149","HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","2024-05-08","Vutrisiran",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07295717","A Study to Evaluate ALN-4285 in Adult Healthy Volunteers","2026-12-29","ALN-4285",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT07463846","A Study to Evaluate ALN-2232 in Participants With Obesity","2027-04-27","ALN-2232",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT07465224","A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus","2027-05-28","ALN-4324",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07575308","HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB","2027-06-30","ALN-6400",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07535606","A Study to Evaluate ALN-4915 in Adult Healthy Volunteers","2027-07-31","ALN-4915",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06393712","A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy","2027-08-09","ALN-APP",{"nctId":72,"briefTitle":73,"date":74,"intervention":55},"NCT06845202","A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM","2027-08-31",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06600321","A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma","2027-09-30","ALN-BCAT",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT07223203","TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy","2027-12-27","Nucresiran",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,151,331,402,424,456,483,517,544,567,585,604,629,649,673,691,716,754,799,821,850,888,924,946,964,988,1012,1030,1048,1066,1090,1125,1143,1161,1190,1208,1226,1252,1270,1288,1306,1331,1349,1439,1523],{"intervention":40,"totalTrials":25,"cells":94},{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":147,"NA":149},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":30,"soonestReadout":39},[104,117,127,138],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"NCT03759379","HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)","COMPLETED",[89],"2020-11-10","2025-11-05","2019-02-14",164,[27,114],"Transthyretin Amyloidosis",[116,40],"Patisiran",{"nctId":81,"briefTitle":82,"status":118,"phases":119,"primaryCompletion":83,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":126},"RECRUITING",[89],"2031-06-12","2025-12-12",125,[124,125],"Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy","hATTR-PN",[84,40],{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},"NCT06679946","A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","ENROLLING_BY_INVITATION",[89],"2028-03-31","2024-12-03",700,[136],"Transthyretin Amyloidosis (ATTR) With Cardiomyopathy",[40],{"nctId":37,"briefTitle":38,"status":139,"phases":140,"primaryCompletion":39,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":145},"ACTIVE_NOT_RECRUITING",[89],"2026-12-02","2019-11-26",655,[136],[40,146],"Sterile Normal Saline",{"trials":148,"activeCount":97},[],{"trials":150,"activeCount":97},[],{"intervention":146,"totalTrials":9,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":272,"PHASE3":286,"PHASE4":327,"NA":329},{"trials":154,"activeCount":97},[],{"trials":156,"activeCount":97},[157,169,181,193,204,215,226,238,248,262],{"nctId":158,"briefTitle":159,"status":107,"phases":160,"primaryCompletion":161,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":167},"NCT02314442","A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)",[87],"2015-05","2015-11","2014-12",70,[166],"Hypercholesterolemia",[168,146],"ALN-PCSSC",{"nctId":170,"briefTitle":171,"status":172,"phases":173,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":179},"NCT02503683","A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease","TERMINATED",[87],"2018-01-03","2015-07-09",26,[178],"Antitrypsin Deficiency Liver Disease",[180,146],"ALN-AAT",{"nctId":182,"briefTitle":183,"status":107,"phases":184,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":191},"NCT01148953","Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis",[87],"2012-01","2012-02","2010-06",32,[190],"Transthyretin Mediated Amyloidosis (ATTR)",[192,146],"ALN-TTR01",{"nctId":194,"briefTitle":195,"status":107,"phases":196,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":202},"NCT01559077","Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects",[87],"2012-06","2012-11","2012-03",17,[15],[203,146],"ALN-TTR02",{"nctId":205,"briefTitle":206,"status":107,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT02452372","A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)",[87],"2017-09-06","2015-05-06",40,[212],"Acute Intermittent Porphyria",[214,146],"givosiran",{"nctId":216,"briefTitle":217,"status":107,"phases":218,"primaryCompletion":219,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":224},"NCT02797847","A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects",[87],"2018-01-12","2016-06-07",80,[223],"Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)",[225,146],"ALN-TTRSC02",{"nctId":227,"briefTitle":228,"status":107,"phases":229,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":236},"NCT02053454","A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers",[87],"2014-03","2014-06","2014-01",12,[235],"Transthyretin (TTR)-Mediated Amyloidosis",[237,146],"patisiran",{"nctId":239,"briefTitle":240,"status":107,"phases":241,"primaryCompletion":199,"completion":242,"start":243,"enrollment":188,"conditions":244,"interventions":246},"NCT01437059","Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)",[87],"2012-09","2011-09",[245],"Elevated LDL-Cholesterol (LDL-C)",[247,146],"ALN-PCS02",{"nctId":249,"briefTitle":250,"status":172,"phases":251,"primaryCompletion":252,"completion":252,"start":253,"enrollment":8,"conditions":254,"interventions":260},"NCT02826018","A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection",[87],"2017-10","2016-06-24",[255,256,257,258,259],"Hepatitis B","Chronic Hepatitis B","Hepatitis B, Chronic","Hepatitis B Infection","HBV",[261,146],"ALN-HBV",{"nctId":263,"briefTitle":264,"status":107,"phases":265,"primaryCompletion":266,"completion":161,"start":267,"enrollment":268,"conditions":269,"interventions":270},"NCT01814839","A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers",[87],"2015-04","2013-03",85,[15],[271,146],"ALN-TTRSC",{"trials":273,"activeCount":97},[274],{"nctId":275,"briefTitle":276,"status":107,"phases":277,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":284},"NCT02352493","A Phase 1\u002F2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH",[87,88],"2016-04","2017-08","2015-01",62,[283],"Paroxysmal Nocturnal Hemoglobinuria (PNH)",[285,146],"ALN-CC5",{"trials":287,"activeCount":326,"soonestReadout":39},[288,299,311,322],{"nctId":289,"briefTitle":290,"status":118,"phases":291,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":296,"interventions":298},"NCT07052903","TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy",[89],"2030-05-28","2032-11-30","2025-07-02",1250,[297],"Transthyretin Amyloidosis With Cardiomyopathy",[84,146],{"nctId":300,"briefTitle":301,"status":107,"phases":302,"primaryCompletion":279,"completion":279,"start":303,"enrollment":304,"conditions":305,"interventions":310},"NCT01960348","APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis",[89],"2013-11",225,[15,27,306,307,308,309],"Amyloid Neuropathies, Familial","Familial Amyloid Polyneuropathies","Amyloid Neuropathies","Amyloidosis, Hereditary, Transthyretin-Related",[237,146],{"nctId":312,"briefTitle":313,"status":107,"phases":314,"primaryCompletion":315,"completion":315,"start":163,"enrollment":316,"conditions":317,"interventions":320},"NCT02319005","ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)",[89],"2017-03-30",206,[318,27,306,308,309,319],"Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)","Familial Transthyretin Cardiac Amyloidosis",[321,146],"Revusiran",{"nctId":37,"briefTitle":38,"status":139,"phases":323,"primaryCompletion":39,"completion":141,"start":142,"enrollment":143,"conditions":324,"interventions":325},[89],[136],[40,146],2,{"trials":328,"activeCount":97},[],{"trials":330,"activeCount":97},[],{"intervention":332,"totalTrials":22,"cells":333},"Zilebesiran",{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":338,"PHASE3":386,"PHASE4":398,"NA":400},{"trials":335,"activeCount":97},[],{"trials":337,"activeCount":97},[],{"trials":339,"activeCount":385,"soonestReadout":354},[340,350,361,374],{"nctId":341,"briefTitle":342,"status":107,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":349},"NCT06423352","A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension",[87,88],"2025-07-17","2024-06-05",36,[348],"Mild to Moderate Hypertension",[332],{"nctId":351,"briefTitle":352,"status":118,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":359},"NCT07553442","A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran",[88],"2028-04-01","2028-10-01","2026-04-27",93,[18],[360,332],"ALN-AGT01 RVR",{"nctId":362,"briefTitle":363,"status":107,"phases":364,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":370},"NCT05103332","Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)",[88],"2023-12-11","2024-09-13","2021-11-05",663,[18],[371,372,373,332],"Indapamide","Amlodipine","Olmesartan",{"nctId":375,"briefTitle":376,"status":107,"phases":377,"primaryCompletion":378,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":384},"NCT06272487","Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)",[88],"2025-06-19","2025-12-01","2024-02-29",375,[383,18],"High Cardiovascular Risk",[332],1,{"trials":387,"activeCount":385,"soonestReadout":392},[388],{"nctId":389,"briefTitle":390,"status":118,"phases":391,"primaryCompletion":392,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":397},"NCT07181109","Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease",[89],"2030-09-30","2025-09-22",11000,[396,18,383],"High Risk Cardiovascular Disease",[332],{"trials":399,"activeCount":97},[],{"trials":401,"activeCount":97},[],{"intervention":84,"totalTrials":326,"cells":403},{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":410,"PHASE4":420,"NA":422},{"trials":405,"activeCount":97},[],{"trials":407,"activeCount":97},[],{"trials":409,"activeCount":97},[],{"trials":411,"activeCount":326,"soonestReadout":83},[412,416],{"nctId":289,"briefTitle":290,"status":118,"phases":413,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":414,"interventions":415},[89],[297],[84,146],{"nctId":81,"briefTitle":82,"status":118,"phases":417,"primaryCompletion":83,"completion":120,"start":121,"enrollment":122,"conditions":418,"interventions":419},[89],[124,125],[84,40],{"trials":421,"activeCount":97},[],{"trials":423,"activeCount":97},[],{"intervention":70,"totalTrials":326,"cells":425},{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":440,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":427,"activeCount":97},[],{"trials":429,"activeCount":385,"soonestReadout":434},[430],{"nctId":431,"briefTitle":432,"status":118,"phases":433,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":439},"NCT05231785","A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD",[87],"2029-04-20","2022-02-04",60,[438],"Early-Onset Alzheimer Disease",[70],{"trials":441,"activeCount":385,"soonestReadout":69},[442],{"nctId":67,"briefTitle":68,"status":118,"phases":443,"primaryCompletion":69,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":449},[88],"2029-12-14","2024-05-17",200,[448],"Cerebral Amyloid Angiopathy",[70],{"trials":451,"activeCount":97},[],{"trials":453,"activeCount":97},[],{"trials":455,"activeCount":97},[],{"intervention":55,"totalTrials":326,"cells":457},{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":459,"activeCount":97},[],{"trials":461,"activeCount":97},[],{"trials":463,"activeCount":326,"soonestReadout":54},[464,472],{"nctId":72,"briefTitle":73,"status":118,"phases":465,"primaryCompletion":74,"completion":74,"start":466,"enrollment":467,"conditions":468,"interventions":471},[87,88],"2025-03-03",144,[469,470],"Obese or Overweight Healthy Volunteers","Type 2 Diabetes Mellitus (T2DM)",[55],{"nctId":52,"briefTitle":53,"status":118,"phases":473,"primaryCompletion":54,"completion":54,"start":474,"enrollment":210,"conditions":475,"interventions":476},[88],"2026-01-15",[470],[55],{"trials":478,"activeCount":97},[],{"trials":480,"activeCount":97},[],{"trials":482,"activeCount":97},[],{"intervention":60,"totalTrials":326,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":511,"PHASE4":513,"NA":515},{"trials":486,"activeCount":97},[],{"trials":488,"activeCount":97},[],{"trials":490,"activeCount":326,"soonestReadout":59},[491,500],{"nctId":57,"briefTitle":58,"status":492,"phases":493,"primaryCompletion":59,"completion":494,"start":495,"enrollment":8,"conditions":496,"interventions":499},"NOT_YET_RECRUITING",[88],"2028-11-29","2026-05-22",[497,498],"Von Willebrand Disease (VWD)","Heavy Menstrual Bleeding (HMB)",[60],{"nctId":501,"briefTitle":502,"status":118,"phases":503,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":510},"NCT06659640","A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)",[87,88],"2028-01-05","2028-06-22","2024-11-07",120,[509],"Hereditary Hemorrhagic Telangiectasia",[60],{"trials":512,"activeCount":97},[],{"trials":514,"activeCount":97},[],{"trials":516,"activeCount":97},[],{"intervention":360,"totalTrials":326,"cells":518},{"EARLY_PHASE1":519,"PHASE1":521,"PHASE2":532,"PHASE3":538,"PHASE4":540,"NA":542},{"trials":520,"activeCount":97},[],{"trials":522,"activeCount":97},[523],{"nctId":524,"briefTitle":525,"status":107,"phases":526,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":531},"NCT06675565","A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers",[87],"2025-09-08","2024-11-05",42,[29],[360],{"trials":533,"activeCount":385,"soonestReadout":354},[534],{"nctId":351,"briefTitle":352,"status":118,"phases":535,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":536,"interventions":537},[88],[18],[360,332],{"trials":539,"activeCount":97},[],{"trials":541,"activeCount":97},[],{"trials":543,"activeCount":97},[],{"intervention":50,"totalTrials":385,"cells":545},{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":547,"activeCount":97},[],{"trials":549,"activeCount":97},[],{"trials":551,"activeCount":385,"soonestReadout":49},[552],{"nctId":47,"briefTitle":48,"status":118,"phases":553,"primaryCompletion":49,"completion":554,"start":555,"enrollment":556,"conditions":557,"interventions":559},[87,88],"2028-03-02","2026-03-02",156,[558],"Obesity",[50,560],"Tirzepatide",{"trials":562,"activeCount":97},[],{"trials":564,"activeCount":97},[],{"trials":566,"activeCount":97},[],{"intervention":560,"totalTrials":385,"cells":568},{"EARLY_PHASE1":569,"PHASE1":571,"PHASE2":573,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":570,"activeCount":97},[],{"trials":572,"activeCount":97},[],{"trials":574,"activeCount":385,"soonestReadout":49},[575],{"nctId":47,"briefTitle":48,"status":118,"phases":576,"primaryCompletion":49,"completion":554,"start":555,"enrollment":556,"conditions":577,"interventions":578},[87,88],[558],[50,560],{"trials":580,"activeCount":97},[],{"trials":582,"activeCount":97},[],{"trials":584,"activeCount":97},[],{"intervention":65,"totalTrials":385,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":596,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":588,"activeCount":97},[],{"trials":590,"activeCount":385,"soonestReadout":64},[591],{"nctId":62,"briefTitle":63,"status":118,"phases":592,"primaryCompletion":64,"completion":64,"start":555,"enrollment":593,"conditions":594,"interventions":595},[87],44,[29],[65],{"trials":597,"activeCount":97},[],{"trials":599,"activeCount":97},[],{"trials":601,"activeCount":97},[],{"trials":603,"activeCount":97},[],{"intervention":605,"totalTrials":385,"cells":606},"ALN-5288",{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":627},{"trials":608,"activeCount":97},[],{"trials":610,"activeCount":385,"soonestReadout":615},[611],{"nctId":612,"briefTitle":613,"status":118,"phases":614,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":620},"NCT07214727","A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease",[87],"2030-03-06","2025-10-15",50,[619],"Alzheimer's Disease",[605],{"trials":622,"activeCount":97},[],{"trials":624,"activeCount":97},[],{"trials":626,"activeCount":97},[],{"trials":628,"activeCount":97},[],{"intervention":45,"totalTrials":385,"cells":630},{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":641,"PHASE3":643,"PHASE4":645,"NA":647},{"trials":632,"activeCount":97},[],{"trials":634,"activeCount":385,"soonestReadout":44},[635],{"nctId":42,"briefTitle":43,"status":118,"phases":636,"primaryCompletion":44,"completion":637,"start":121,"enrollment":638,"conditions":639,"interventions":640},[87],"2027-03-23",76,[29],[45],{"trials":642,"activeCount":97},[],{"trials":644,"activeCount":97},[],{"trials":646,"activeCount":97},[],{"trials":648,"activeCount":97},[],{"intervention":79,"totalTrials":385,"cells":650},{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":671},{"trials":652,"activeCount":97},[],{"trials":654,"activeCount":385,"soonestReadout":78},[655],{"nctId":76,"briefTitle":77,"status":118,"phases":656,"primaryCompletion":78,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":663},[87],"2027-10-31","2024-12-30",158,[661,662],"Advanced Hepatocellular Carcinoma","Metastatic Hepatocellular Carcinoma",[79,664],"Pembrolizumab",{"trials":666,"activeCount":97},[],{"trials":668,"activeCount":97},[],{"trials":670,"activeCount":97},[],{"trials":672,"activeCount":97},[],{"intervention":664,"totalTrials":385,"cells":674},{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":683,"PHASE3":685,"PHASE4":687,"NA":689},{"trials":676,"activeCount":97},[],{"trials":678,"activeCount":385,"soonestReadout":78},[679],{"nctId":76,"briefTitle":77,"status":118,"phases":680,"primaryCompletion":78,"completion":657,"start":658,"enrollment":659,"conditions":681,"interventions":682},[87],[661,662],[79,664],{"trials":684,"activeCount":97},[],{"trials":686,"activeCount":97},[],{"trials":688,"activeCount":97},[],{"trials":690,"activeCount":97},[],{"intervention":692,"totalTrials":385,"cells":693},"ALN-HTT02",{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":708,"PHASE3":710,"PHASE4":712,"NA":714},{"trials":695,"activeCount":97},[],{"trials":697,"activeCount":385,"soonestReadout":702},[698],{"nctId":699,"briefTitle":700,"status":118,"phases":701,"primaryCompletion":702,"completion":702,"start":703,"enrollment":704,"conditions":705,"interventions":707},"NCT06585449","A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease",[87],"2028-07-05","2024-10-14",66,[706],"Huntington's Disease",[692],{"trials":709,"activeCount":97},[],{"trials":711,"activeCount":97},[],{"trials":713,"activeCount":97},[],{"trials":715,"activeCount":97},[],{"intervention":321,"totalTrials":30,"cells":717},{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":744,"PHASE4":750,"NA":752},{"trials":719,"activeCount":97},[],{"trials":721,"activeCount":97},[],{"trials":723,"activeCount":97},[724,733],{"nctId":725,"briefTitle":726,"status":107,"phases":727,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":732},"NCT02292186","A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis",[88],"2017-02-22","2014-10",25,[15],[321],{"nctId":734,"briefTitle":735,"status":107,"phases":736,"primaryCompletion":737,"completion":737,"start":738,"enrollment":233,"conditions":739,"interventions":743},"NCT02595983","The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant",[88],"2017-02-06","2015-10",[235,740,741,742],"Familial Amyloidotic Polyneuropathy (FAP)","ATTR Amyloidosis","Familial Amyloid Neuropathies",[321],{"trials":745,"activeCount":97},[746],{"nctId":312,"briefTitle":313,"status":107,"phases":747,"primaryCompletion":315,"completion":315,"start":163,"enrollment":316,"conditions":748,"interventions":749},[89],[318,27,306,308,309,319],[321,146],{"trials":751,"activeCount":97},[],{"trials":753,"activeCount":97},[],{"intervention":755,"totalTrials":30,"cells":756},"ALN-RSV01",{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":758,"activeCount":97},[],{"trials":760,"activeCount":97},[],{"trials":762,"activeCount":97},[763,774,783],{"nctId":764,"briefTitle":765,"status":107,"phases":766,"primaryCompletion":767,"completion":768,"start":769,"enrollment":770,"conditions":771,"interventions":772},"NCT01065935","Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)",[88],"2012-04","2012-05","2010-02",87,[34],[755,773],"Normal Saline",{"nctId":775,"briefTitle":776,"status":107,"phases":777,"completion":778,"start":779,"enrollment":780,"conditions":781,"interventions":782},"NCT00496821","Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus",[88],"2007-11","2007-07",88,[34],[755],{"nctId":784,"briefTitle":785,"status":107,"phases":786,"primaryCompletion":787,"completion":788,"start":789,"enrollment":8,"conditions":790,"interventions":791},"NCT00658086","Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)",[88],"2009-04","2009-06","2008-04",[34],[755,792],"normal saline",{"trials":794,"activeCount":97},[],{"trials":796,"activeCount":97},[],{"trials":798,"activeCount":97},[],{"intervention":773,"totalTrials":326,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":815,"PHASE4":817,"NA":819},{"trials":802,"activeCount":97},[],{"trials":804,"activeCount":97},[],{"trials":806,"activeCount":97},[807,811],{"nctId":764,"briefTitle":765,"status":107,"phases":808,"primaryCompletion":767,"completion":768,"start":769,"enrollment":770,"conditions":809,"interventions":810},[88],[34],[755,773],{"nctId":784,"briefTitle":785,"status":107,"phases":812,"primaryCompletion":787,"completion":788,"start":789,"enrollment":8,"conditions":813,"interventions":814},[88],[34],[755,792],{"trials":816,"activeCount":97},[],{"trials":818,"activeCount":97},[],{"trials":820,"activeCount":97},[],{"intervention":822,"totalTrials":326,"cells":823},"ALN-TTR02 (patisiran) administered by intravenous (IV)",{"EARLY_PHASE1":824,"PHASE1":826,"PHASE2":832,"PHASE3":844,"PHASE4":846,"NA":848},{"trials":825,"activeCount":97},[],{"trials":827,"activeCount":97},[828],{"nctId":194,"briefTitle":195,"status":107,"phases":829,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":830,"interventions":831},[87],[15],[203,146],{"trials":833,"activeCount":97},[834],{"nctId":835,"briefTitle":836,"status":107,"phases":837,"primaryCompletion":838,"completion":839,"start":840,"enrollment":841,"conditions":842,"interventions":843},"NCT01961921","The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)",[88],"2016-07","2016-08","2013-10",27,[15],[822],{"trials":845,"activeCount":97},[],{"trials":847,"activeCount":97},[],{"trials":849,"activeCount":97},[],{"intervention":851,"totalTrials":326,"cells":852},"Cemdisiran",{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":882,"PHASE4":884,"NA":886},{"trials":854,"activeCount":97},[],{"trials":856,"activeCount":97},[],{"trials":858,"activeCount":97},[859,872],{"nctId":860,"briefTitle":861,"status":172,"phases":862,"primaryCompletion":863,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":871},"NCT03841448","A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)",[88],"2022-03-17","2023-06-27","2019-09-30",31,[868,869,870],"IgA Nephropathy (IgAN)","Berger Disease","Glomerulonephritis, IgA",[851],{"nctId":873,"briefTitle":874,"status":875,"phases":876,"primaryCompletion":877,"completion":877,"start":878,"enrollment":97,"conditions":879,"interventions":881},"NCT03303313","A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome","WITHDRAWN",[88],"2018-09-12","2017-09-19",[880],"Atypical Hemolytic Uremic Syndrome",[851],{"trials":883,"activeCount":97},[],{"trials":885,"activeCount":97},[],{"trials":887,"activeCount":97},[],{"intervention":889,"totalTrials":326,"cells":890},"ALN-AGT01",{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":906,"PHASE3":918,"PHASE4":920,"NA":922},{"trials":892,"activeCount":97},[],{"trials":894,"activeCount":97},[895],{"nctId":896,"briefTitle":897,"status":107,"phases":898,"primaryCompletion":899,"completion":900,"start":901,"enrollment":902,"conditions":903,"interventions":904},"NCT03934307","A Study to Evaluate ALN-AGT01 in Patients With Hypertension",[87],"2022-04-20","2023-01-04","2019-05-01",124,[18],[889,905],"Irbesartan",{"trials":907,"activeCount":97},[908],{"nctId":909,"briefTitle":910,"status":107,"phases":911,"primaryCompletion":912,"completion":913,"start":914,"enrollment":915,"conditions":916,"interventions":917},"NCT04936035","A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension",[88],"2023-04-04","2024-12-05","2021-07-07",394,[18],[889],{"trials":919,"activeCount":97},[],{"trials":921,"activeCount":97},[],{"trials":923,"activeCount":97},[],{"intervention":925,"totalTrials":385,"cells":926},"ALN-TTRSC (revusiran) for subcutaneous administration",{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":940,"PHASE4":942,"NA":944},{"trials":928,"activeCount":97},[],{"trials":930,"activeCount":97},[],{"trials":932,"activeCount":97},[933],{"nctId":934,"briefTitle":935,"status":107,"phases":936,"primaryCompletion":729,"completion":280,"start":937,"enrollment":176,"conditions":938,"interventions":939},"NCT01981837","Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis",[88],"2013-12",[15],[925],{"trials":941,"activeCount":97},[],{"trials":943,"activeCount":97},[],{"trials":945,"activeCount":97},[],{"intervention":285,"totalTrials":385,"cells":947},{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":958,"PHASE4":960,"NA":962},{"trials":949,"activeCount":97},[],{"trials":951,"activeCount":97},[],{"trials":953,"activeCount":97},[954],{"nctId":275,"briefTitle":276,"status":107,"phases":955,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":956,"interventions":957},[87,88],[283],[285,146],{"trials":959,"activeCount":97},[],{"trials":961,"activeCount":97},[],{"trials":963,"activeCount":97},[],{"intervention":965,"totalTrials":385,"cells":966},"ALN-XDH",{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":982,"PHASE4":984,"NA":986},{"trials":968,"activeCount":97},[],{"trials":970,"activeCount":97},[],{"trials":972,"activeCount":97},[973],{"nctId":974,"briefTitle":975,"status":172,"phases":976,"primaryCompletion":977,"completion":977,"start":978,"enrollment":593,"conditions":979,"interventions":981},"NCT05256810","A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout",[87,88],"2023-01-25","2022-02-25",[980],"Gout",[965],{"trials":983,"activeCount":97},[],{"trials":985,"activeCount":97},[],{"trials":987,"activeCount":97},[],{"intervention":989,"totalTrials":385,"cells":990},"ALN-AAT02",{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":1006,"PHASE4":1008,"NA":1010},{"trials":992,"activeCount":97},[],{"trials":994,"activeCount":97},[],{"trials":996,"activeCount":97},[997],{"nctId":998,"briefTitle":999,"status":172,"phases":1000,"primaryCompletion":1001,"completion":1001,"start":1002,"enrollment":188,"conditions":1003,"interventions":1005},"NCT03767829","A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease",[87,88],"2020-06-25","2018-12-05",[1004],"ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease",[989,989],{"trials":1007,"activeCount":97},[],{"trials":1009,"activeCount":97},[],{"trials":1011,"activeCount":97},[],{"intervention":371,"totalTrials":385,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":1015,"activeCount":97},[],{"trials":1017,"activeCount":97},[],{"trials":1019,"activeCount":97},[1020],{"nctId":362,"briefTitle":363,"status":107,"phases":1021,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":1022,"interventions":1023},[88],[18],[371,372,373,332],{"trials":1025,"activeCount":97},[],{"trials":1027,"activeCount":97},[],{"trials":1029,"activeCount":97},[],{"intervention":372,"totalTrials":385,"cells":1031},{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1042,"PHASE4":1044,"NA":1046},{"trials":1033,"activeCount":97},[],{"trials":1035,"activeCount":97},[],{"trials":1037,"activeCount":97},[1038],{"nctId":362,"briefTitle":363,"status":107,"phases":1039,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":1040,"interventions":1041},[88],[18],[371,372,373,332],{"trials":1043,"activeCount":97},[],{"trials":1045,"activeCount":97},[],{"trials":1047,"activeCount":97},[],{"intervention":373,"totalTrials":385,"cells":1049},{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1051,"activeCount":97},[],{"trials":1053,"activeCount":97},[],{"trials":1055,"activeCount":97},[1056],{"nctId":362,"briefTitle":363,"status":107,"phases":1057,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":1058,"interventions":1059},[88],[18],[371,372,373,332],{"trials":1061,"activeCount":97},[],{"trials":1063,"activeCount":97},[],{"trials":1065,"activeCount":97},[],{"intervention":1067,"totalTrials":385,"cells":1068},"ALN-KHK",{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1070,"activeCount":97},[],{"trials":1072,"activeCount":97},[],{"trials":1074,"activeCount":97},[1075],{"nctId":1076,"briefTitle":1077,"status":172,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1083},"NCT05761301","A Phase 1\u002F2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM",[87,88],"2025-04-03","2023-03-10",49,[470],[1067],{"trials":1085,"activeCount":97},[],{"trials":1087,"activeCount":97},[],{"trials":1089,"activeCount":97},[],{"intervention":1091,"totalTrials":326,"cells":1092},"ALN-VSP02",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1117,"PHASE3":1119,"PHASE4":1121,"NA":1123},{"trials":1094,"activeCount":97},[],{"trials":1096,"activeCount":97},[1097,1108],{"nctId":1098,"briefTitle":1099,"status":107,"phases":1100,"primaryCompletion":1101,"completion":1102,"start":1103,"enrollment":1104,"conditions":1105,"interventions":1107},"NCT00882180","Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement",[87],"2011-07","2011-08","2009-03",41,[1106],"Solid Tumors",[1091],{"nctId":1109,"briefTitle":1110,"status":107,"phases":1111,"primaryCompletion":1112,"completion":242,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1116},"NCT01158079","Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment",[87],"2012-08","2010-07",7,[1106],[1091],{"trials":1118,"activeCount":97},[],{"trials":1120,"activeCount":97},[],{"trials":1122,"activeCount":97},[],{"trials":1124,"activeCount":97},[],{"intervention":168,"totalTrials":385,"cells":1126},{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1135,"PHASE3":1137,"PHASE4":1139,"NA":1141},{"trials":1128,"activeCount":97},[],{"trials":1130,"activeCount":97},[1131],{"nctId":158,"briefTitle":159,"status":107,"phases":1132,"primaryCompletion":161,"completion":162,"start":163,"enrollment":164,"conditions":1133,"interventions":1134},[87],[166],[168,146],{"trials":1136,"activeCount":97},[],{"trials":1138,"activeCount":97},[],{"trials":1140,"activeCount":97},[],{"trials":1142,"activeCount":97},[],{"intervention":180,"totalTrials":385,"cells":1144},{"EARLY_PHASE1":1145,"PHASE1":1147,"PHASE2":1153,"PHASE3":1155,"PHASE4":1157,"NA":1159},{"trials":1146,"activeCount":97},[],{"trials":1148,"activeCount":97},[1149],{"nctId":170,"briefTitle":171,"status":172,"phases":1150,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":1151,"interventions":1152},[87],[178],[180,146],{"trials":1154,"activeCount":97},[],{"trials":1156,"activeCount":97},[],{"trials":1158,"activeCount":97},[],{"trials":1160,"activeCount":97},[],{"intervention":1162,"totalTrials":385,"cells":1163},"5-probe cocktail",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1182,"PHASE3":1184,"PHASE4":1186,"NA":1188},{"trials":1165,"activeCount":97},[],{"trials":1167,"activeCount":97},[1168],{"nctId":1169,"briefTitle":1170,"status":107,"phases":1171,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":12,"conditions":1175,"interventions":1180},"NCT03505853","A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)",[87],"2018-11-16","2019-01-10","2018-04-26",[1176,1177,1178,1179],"Acute Intermittent Porphyria (AIP)","Acute Hepatic Porphyria (AHP)","Porphyria, Acute Intermittent","Acute Porphyria",[1181,1162],"Givosiran",{"trials":1183,"activeCount":97},[],{"trials":1185,"activeCount":97},[],{"trials":1187,"activeCount":97},[],{"trials":1189,"activeCount":97},[],{"intervention":192,"totalTrials":385,"cells":1191},{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1200,"PHASE3":1202,"PHASE4":1204,"NA":1206},{"trials":1193,"activeCount":97},[],{"trials":1195,"activeCount":97},[1196],{"nctId":182,"briefTitle":183,"status":107,"phases":1197,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":1198,"interventions":1199},[87],[190],[192,146],{"trials":1201,"activeCount":97},[],{"trials":1203,"activeCount":97},[],{"trials":1205,"activeCount":97},[],{"trials":1207,"activeCount":97},[],{"intervention":225,"totalTrials":385,"cells":1209},{"EARLY_PHASE1":1210,"PHASE1":1212,"PHASE2":1218,"PHASE3":1220,"PHASE4":1222,"NA":1224},{"trials":1211,"activeCount":97},[],{"trials":1213,"activeCount":97},[1214],{"nctId":216,"briefTitle":217,"status":107,"phases":1215,"primaryCompletion":219,"completion":219,"start":220,"enrollment":221,"conditions":1216,"interventions":1217},[87],[223],[225,146],{"trials":1219,"activeCount":97},[],{"trials":1221,"activeCount":97},[],{"trials":1223,"activeCount":97},[],{"trials":1225,"activeCount":97},[],{"intervention":1227,"totalTrials":385,"cells":1228},"ALN-HSD",{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1244,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1230,"activeCount":97},[],{"trials":1232,"activeCount":97},[1233],{"nctId":1234,"briefTitle":1235,"status":172,"phases":1236,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":19,"conditions":1240,"interventions":1243},"NCT04565717","A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)",[87],"2023-01-06","2023-12-21","2020-10-09",[1241,1242],"Nonalcoholic Steatohepatitis","NASH",[1227],{"trials":1245,"activeCount":97},[],{"trials":1247,"activeCount":97},[],{"trials":1249,"activeCount":97},[],{"trials":1251,"activeCount":97},[],{"intervention":247,"totalTrials":385,"cells":1253},{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1262,"PHASE3":1264,"PHASE4":1266,"NA":1268},{"trials":1255,"activeCount":97},[],{"trials":1257,"activeCount":97},[1258],{"nctId":239,"briefTitle":240,"status":107,"phases":1259,"primaryCompletion":199,"completion":242,"start":243,"enrollment":188,"conditions":1260,"interventions":1261},[87],[245],[247,146],{"trials":1263,"activeCount":97},[],{"trials":1265,"activeCount":97},[],{"trials":1267,"activeCount":97},[],{"trials":1269,"activeCount":97},[],{"intervention":261,"totalTrials":385,"cells":1271},{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1280,"PHASE3":1282,"PHASE4":1284,"NA":1286},{"trials":1273,"activeCount":97},[],{"trials":1275,"activeCount":97},[1276],{"nctId":249,"briefTitle":250,"status":172,"phases":1277,"primaryCompletion":252,"completion":252,"start":253,"enrollment":8,"conditions":1278,"interventions":1279},[87],[255,256,257,258,259],[261,146],{"trials":1281,"activeCount":97},[],{"trials":1283,"activeCount":97},[],{"trials":1285,"activeCount":97},[],{"trials":1287,"activeCount":97},[],{"intervention":271,"totalTrials":385,"cells":1289},{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1298,"PHASE3":1300,"PHASE4":1302,"NA":1304},{"trials":1291,"activeCount":97},[],{"trials":1293,"activeCount":97},[1294],{"nctId":263,"briefTitle":264,"status":107,"phases":1295,"primaryCompletion":266,"completion":161,"start":267,"enrollment":268,"conditions":1296,"interventions":1297},[87],[15],[271,146],{"trials":1299,"activeCount":97},[],{"trials":1301,"activeCount":97},[],{"trials":1303,"activeCount":97},[],{"trials":1305,"activeCount":97},[],{"intervention":1307,"totalTrials":385,"cells":1308},"ALN-TTRSC04",{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1323,"PHASE3":1325,"PHASE4":1327,"NA":1329},{"trials":1310,"activeCount":97},[],{"trials":1312,"activeCount":97},[1313],{"nctId":1314,"briefTitle":1315,"status":107,"phases":1316,"primaryCompletion":1317,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1322},"NCT05661916","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects",[87],"2025-09-30","2023-01-16",96,[1321],"Transthyretin-Mediated Amyloidosis",[1307],{"trials":1324,"activeCount":97},[],{"trials":1326,"activeCount":97},[],{"trials":1328,"activeCount":97},[],{"trials":1330,"activeCount":97},[],{"intervention":905,"totalTrials":385,"cells":1332},{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1341,"PHASE3":1343,"PHASE4":1345,"NA":1347},{"trials":1334,"activeCount":97},[],{"trials":1336,"activeCount":97},[1337],{"nctId":896,"briefTitle":897,"status":107,"phases":1338,"primaryCompletion":899,"completion":900,"start":901,"enrollment":902,"conditions":1339,"interventions":1340},[87],[18],[889,905],{"trials":1342,"activeCount":97},[],{"trials":1344,"activeCount":97},[],{"trials":1346,"activeCount":97},[],{"trials":1348,"activeCount":97},[],{"intervention":116,"totalTrials":12,"cells":1350},{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1359,"PHASE3":1368,"PHASE4":1408,"NA":1410},{"trials":1352,"activeCount":97},[],{"trials":1354,"activeCount":97},[1355],{"nctId":227,"briefTitle":228,"status":107,"phases":1356,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":1357,"interventions":1358},[87],[235],[237,146],{"trials":1360,"activeCount":97},[1361],{"nctId":1362,"briefTitle":1363,"status":107,"phases":1364,"primaryCompletion":840,"completion":232,"start":768,"enrollment":1365,"conditions":1366,"interventions":1367},"NCT01617967","Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis",[88],29,[15],[116],{"trials":1369,"activeCount":97},[1370,1380,1384,1394,1398],{"nctId":1371,"briefTitle":1372,"status":107,"phases":1373,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":1376,"conditions":1377,"interventions":1379},"NCT02510261","The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)",[89],"2022-11-23","2015-07-16",211,[1378],"Amyloidosis",[116],{"nctId":300,"briefTitle":301,"status":107,"phases":1381,"primaryCompletion":279,"completion":279,"start":303,"enrollment":304,"conditions":1382,"interventions":1383},[89],[15,27,306,307,308,309],[237,146],{"nctId":1385,"briefTitle":1386,"status":107,"phases":1387,"primaryCompletion":1388,"completion":1389,"start":1390,"enrollment":1391,"conditions":1392,"interventions":1393},"NCT03997383","APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)",[89],"2022-06-20","2025-12-24","2019-09-04",360,[136],[116],{"nctId":105,"briefTitle":106,"status":107,"phases":1395,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":1396,"interventions":1397},[89],[27,114],[116,40],{"nctId":1399,"briefTitle":1400,"status":107,"phases":1401,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":8,"conditions":1405,"interventions":1407},"NCT03862807","Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant",[89],"2020-10-06","2020-10-20","2019-03-27",[1406,114],"Amyloidosis, Familial",[116],{"trials":1409,"activeCount":97},[],{"trials":1411,"activeCount":97},[1412,1423,1432],{"nctId":1413,"briefTitle":1414,"status":107,"phases":1415,"primaryCompletion":1416,"completion":1416,"start":1417,"enrollment":1418,"conditions":1419,"interventions":1422},"NCT04201418","A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation",[],"2022-05-24","2019-12-18",67,[1420,1421],"Hereditary Transthyretin-mediated (ATTRv) Amyloidosis","Polyneuropathy",[116],{"nctId":1424,"briefTitle":1425,"status":1426,"phases":1427,"conditions":1428,"interventions":1431},"NCT05505838","Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy","NO_LONGER_AVAILABLE",[],[1429,1430],"Transthyretin-mediated Amyloidosis With Cardiomyopathy","ATTR Amyloidosis With Cardiomyopathy",[116],{"nctId":1433,"briefTitle":1434,"status":1435,"phases":1436,"conditions":1437,"interventions":1438},"NCT02939820","Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)","APPROVED_FOR_MARKETING",[],[15,27,306,307,308,309],[237],{"intervention":1440,"totalTrials":1114,"cells":1441},"Lumasiran",{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1480,"PHASE4":1513,"NA":1515},{"trials":1443,"activeCount":97},[],{"trials":1445,"activeCount":97},[],{"trials":1447,"activeCount":97},[1448,1461,1470],{"nctId":1449,"briefTitle":1450,"status":107,"phases":1451,"primaryCompletion":1452,"completion":1452,"start":1453,"enrollment":1454,"conditions":1455,"interventions":1460},"NCT03350451","An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1",[88],"2023-02-07","2018-04-04",20,[1456,24,1457,1458,1459],"PH1","RNAi Therapeutic","siRNA","AGT",[1440],{"nctId":1462,"briefTitle":1463,"status":107,"phases":1464,"primaryCompletion":1465,"completion":1465,"start":1466,"enrollment":1467,"conditions":1468,"interventions":1469},"NCT02706886","Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1",[87,88],"2019-01-23","2016-03-08",52,[32],[1440],{"nctId":1471,"briefTitle":1472,"status":172,"phases":1473,"primaryCompletion":1474,"completion":1474,"start":1475,"enrollment":326,"conditions":1476,"interventions":1479},"NCT05161936","A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels",[88],"2022-11-01","2022-01-27",[1477,1478],"Recurrent Calcium Oxalate Kidney Stone Disease","Elevated Urinary Oxalate Levels",[1440],{"trials":1481,"activeCount":97},[1482,1493,1503],{"nctId":1483,"briefTitle":1484,"status":107,"phases":1485,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":1489,"conditions":1490,"interventions":1492},"NCT04152200","A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1",[89],"2021-05-18","2025-06-23","2020-01-21",21,[1491,24],"Primary Hyperoxaluria Type 1",[1440],{"nctId":1494,"briefTitle":1495,"status":107,"phases":1496,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1500,"conditions":1501,"interventions":1502},"NCT03681184","A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1",[89],"2019-11-05","2024-01-12","2018-11-27",39,[32],[1440],{"nctId":1504,"briefTitle":1505,"status":107,"phases":1506,"primaryCompletion":1507,"completion":1508,"start":1509,"enrollment":1510,"conditions":1511,"interventions":1512},"NCT03905694","A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1",[89],"2020-06-29","2024-07-26","2019-04-22",18,[24,32],[1440],{"trials":1514,"activeCount":97},[],{"trials":1516,"activeCount":97},[1517],{"nctId":1518,"briefTitle":1519,"status":1435,"phases":1520,"conditions":1521,"interventions":1522},"NCT04125472","Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1",[],[24],[1440],{"intervention":1181,"totalTrials":22,"cells":1524},{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1537,"PHASE3":1546,"PHASE4":1561,"NA":1563},{"trials":1526,"activeCount":97},[],{"trials":1528,"activeCount":97},[1529,1533],{"nctId":1169,"briefTitle":1170,"status":107,"phases":1530,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":12,"conditions":1531,"interventions":1532},[87],[1176,1177,1178,1179],[1181,1162],{"nctId":205,"briefTitle":206,"status":107,"phases":1534,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":1535,"interventions":1536},[87],[212],[214,146],{"trials":1538,"activeCount":97},[1539],{"nctId":1540,"briefTitle":1541,"status":107,"phases":1542,"primaryCompletion":367,"completion":367,"start":1543,"enrollment":11,"conditions":1544,"interventions":1545},"NCT02949830","A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)",[87,88],"2016-10",[212],[1181],{"trials":1547,"activeCount":97},[1548],{"nctId":1549,"briefTitle":1550,"status":107,"phases":1551,"primaryCompletion":1552,"completion":1553,"start":1554,"enrollment":1555,"conditions":1556,"interventions":1560},"NCT03338816","ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)",[89],"2019-01-31","2021-05-31","2017-11-16",94,[21,212,1178,1179,1557,1558,1559],"Hereditary Coproporphyria (HCP)","Variegate Porphyria (VP)","ALA Dehydratase Deficient Porphyria (ADP)",[1181],{"trials":1562,"activeCount":97},[],{"trials":1564,"activeCount":97},[1565],{"nctId":1566,"briefTitle":1567,"status":1435,"phases":1568,"conditions":1569,"interventions":1570},"NCT04056481","Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria",[],[21],[1181]]